Lymphoma, T-Cell, Peripheral: all 607 studies

Page 5 of 7. Open to participants first (133), then studies with results posted, then the rest; newest registration first within each.

• Chidamide Combined With PECM in Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)Status unknownNCT03321890Phase 2
• Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin LymphomaCompletedNCT03302728Phase 1
• Minimal Residual Disease in Peripheral T-cell LymphomaCompletedNCT03297697
• Chidamide With PET Regimen for Angioimmunoblastic T Cell Lymphoma (PET: Prednisone, Etoposide and Thalidomide)Status unknownNCT03273452Phase 2
• Chidamide With CHOP Regimen for de Novo PTCL Patients (CHOP: Cyclophosphamide, Etoposide, Vincristine and Prednisone; PTCL: Peripheral T Cell Lymphoma)Status unknownNCT03268889Not applicable
• B-MAD Chemotherapy in Newly-diagnosed Extranodal NK/ T-cell LymphomaCompletedNCT03246750Phase 1/2
• Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell LymphomaWithdrawnNCT03235869Early Phase 1
• CHP-BV Followed by Consolidation With High-dose Therapy / ASCT as Frontline Treatment of Patients With EATL Type 1.CompletedNCT03217643Phase 2
• Phase I Trial of Selinexor (KPT-330) and Ifosfamide, Carboplatin, Etoposide (ICE) in Peripheral T-cell LymphomaCompletedNCT03212937Phase 1
• T-cell Brazil: Prospective Collection of Data in T-cell Lymphomas PatientsStatus unknownNCT03207789
• Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell LymphomasWithdrawnNCT03205891Phase 1
• Mindfulness Interventions and Cutaneous T Cell Lymphoma (CTCL)TerminatedNCT03174808Not applicable
• A Pralatrexate Study in Asian Patients With Peripheral T-cell Lymphoma After Prior TherapyStatus unknownNCT03150602Phase 4
• Evaluation of the Combination of Romidepsin and Carfilzomib in Relapsed/Refractory Peripheral T Cell Lymphoma PatientsCompletedNCT03141203Phase 1/2
• Treatment of Relapsed or Refractory Natural Killer/T Cell LymphomaStatus unknownNCT03107962Phase 2
• Effectiveness of Circulating DNA for Predicting the Relapse and Overall Survival in NHL PatientsStatus unknownNCT03079947
• Social Media-based Active Self-report on Incidence and Outcomes of Adverse Events in NK/TCL PatientsCompletedNCT03079544
• Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell LymphomasStatus unknownNCT03071822Phase 4
• 18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Peripheral T-cell LymphomaStatus unknownNCT03051581Not applicable
• Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Peripheral T-cell LymphomaStatus unknownNCT03051568Not applicable
• Risk Stratification of Nodal PTCLCompletedNCT03040206
• Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma PatientsStatus unknownNCT03023358Phase 3
• The Value and Mechanisms for Monocytes Subpopulations in Predicting the Prognosis of LymphomasStatus unknownNCT03000738
• Chidamide Plus CHOEP Combined With Upfront ASCT in Untreated Peripheral T-cell LymphomaStatus unknownNCT02987244Phase 1/2
• Chidamide for Refractory/Relapsed Peripheral T Cell LymphomaStatus unknownNCT02944812Phase 2
• Chidamide Combined With Cyclophosphamide, Prednisone, Thalidomide in Treatment of Fragile Patients With Relapse/Refratory Peripheral T Cell LymphomaStatus unknownNCT02879526Phase 2
• Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell LymphomasWithdrawnNCT02875002Phase 1
• Chidamide With ICE Regimen for Relapsed/Refractory Peripheral T Cell LymphomaStatus unknownNCT02856997Phase 2
• Pegaspargase and Methotrexate Based Regimens for Newly Diagnosed Extranodal NK/T Cell LymphomaCompletedNCT02825147Phase 2
• Clinical Trial of Chidamide Combined With CHOP in Peripheral T-cell Lymphoma PatientsCompletedNCT02809573Phase 1
• Bortezomib With Combination of Gemcitabine, Ifosfamide and Oxaliplatin in Untreated NK/T Cell LymphomaTerminatedNCT02808091Phase 2
• A Retrospective Study of Clinical, Phenotypic and Genetic Factors of Peripheral T-Cell LymphomasCompletedNCT02788916
• MEDA Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation for Stage IV Natural Killer/T-cell LymphomaCompletedNCT02764281Not applicable
• Chidamide Plus Chemotherapy in the Treatment of Peripheral T-cell LymphomaStatus unknownNCT02753543Phase 2
• CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and LymphomaStatus unknownNCT02742727Phase 1/2
• GELAD Chemotherapy and Sandwiched Radiotherapy in the Treatment of Stage IE/IIE Natural Killer/T-cell LymphomaCompletedNCT02733458Not applicable
• DS-3201b in Participants With LymphomasActive, not recruitingNCT02732275Phase 1
• Intercontinental Cooperative Non-Hodgkin T-cell Lymphoma Prospective Registry StudyCompletedNCT02691351
• Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin LymphomaCompletedNCT02652715Not applicable
• MESA Versus ESA in the Treatment of Early Stage NK/T-cell LymphomaStatus unknownNCT02631239Phase 3
• A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL)CompletedNCT02594267Phase 1
• Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL)CompletedNCT02593045Phase 1
• Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLLCompletedNCT02580552Phase 1
• Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic MalignanciesCompletedNCT02576496Phase 1
• Trial of IPGDP Regimen Chemotherapy in Patients With Extranodal Natural Killer/T-Cell Lymphoma, Nasal TypeStatus unknownNCT02560441Phase 2
• Study on Therapy With Dimethylfumarate (DMF) in Patients With Cutaneous T Cell Lymphoma (CTCL)CompletedNCT02546440Phase 2
• VP-16, Ifosfamide, Dexamethasone, L-asparaginase Chemotherapy in Patients With Extranodal Natural Killer T Cell Lymphoma (VIDL+ASCT)Status unknownNCT02544425Phase 2
• NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT)Status unknownNCT02542124Phase 2
• CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCLStatus unknownNCT02533700Phase 2
• Benefit of Allogeneic Haematopoietic Stem Cells in Cutaneous T-cell Lymphomas Epidermotropic With Advanced Stage and Poor PrognosisActive, not recruitingNCT02520908
• Endostar Aggressive Treatment of Peripheral T-cell Lymphoma (PTCL) Phase II Clinical StudyStatus unknownNCT02520219Phase 2
• Romidepsin Maintenance After Allogeneic Stem Cell TransplantationCompletedNCT02512497Phase 1
• Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell LymphomasStatus unknownNCT02495415Phase 2
• Compare Efficacy of CHOP Versus Fractionated ICED in Transplant-eligible Patients With Previously Untreated PTCLStatus unknownNCT02445404Phase 2
• Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-cell LymphomaCompletedNCT02424045Phase 2
• GDP in Frontline Chemotherapy for Patients With PTCL-NOSStatus unknownNCT02404571Phase 2
• International Extranodal NK/T-cell Lymphoma ProjectCompletedNCT02386813
• Cohort of Peripheral T Cell LymphomaStatus unknownNCT02364466
• Efficacy and Safety Study of P-Gemox vs.EPOCH as First-line Chemotherapy to Treat NK/T-cell Lymphoma With Early StageTerminatedNCT02359162Phase 3
• Doxycycline for the Treatment of Cutaneous T-Cell LymphomaTerminatedNCT02341209Phase 2
• Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell LymphomasTerminatedNCT02323659Phase 4
• Study of Ibrutinib in Relapsed and Refractory T-cell LymphomaCompletedNCT02309580Phase 1
• Effectiveness of Imiquimod Topical Cream in Early Stage Cutaneous T-cell LymphomaWithdrawnNCT02301494Not applicable
• Radiotherapy Combined With GDP Chemotherapy in Stage I/II Extranodal Natural Killer/T-cell LymphomaCompletedNCT02276248Phase 2
• Mild-dose IMRT for Early-staged Extranodal Nasal-type NK/T-cell Lymphoma With CR Tumor After GELOX ChemotherapyStatus unknownNCT02229682Phase 2
• Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell LymphomasCompletedNCT02223208Phase 1/2
• Efficacy, Safety and Tolerability Study of SHAPE in IA, IB or IIA Cutaneous T-cell LymphomaStatus unknownNCT02213861Phase 2
• Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL)CompletedNCT02192021Phase 1
• Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive LymphomasCompletedNCT02181218Phase 1
• CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin LymphomaCompletedNCT02168140Phase 1
• Carfilzomib Plus Belinostat in Relapsed/Refractory NHLCompletedNCT02142530Phase 1
• Phase II Study of Folotyn With Leucovorin to Prevent/Reduce Mucositis in Patients With Hematological MalignanciesCompletedNCT02106650Phase 2
• A Blood and Tissue Sample Collection Study of Patients Who Have Inflammatory Bowel Disease, Who Have Been Treated With Adalimumab and Who Developed Hepatosplenic T-Cell LymphomaWithdrawnNCT02087878
• PEG-ASP+Gemox Regimen and Thalidomide for NK/T LymphomaStatus unknownNCT02085655Phase 3
• Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell LymphomaTerminatedNCT02061449Phase 1
• Helical Irradiation of Total Skin (HITS) for Cutaneous LymphomaStatus unknownNCT02039895Not applicable
• Phase I/II Clinical Study of Pralatrexate in Japanese Patients With Relapsed or Refractory Peripheral T-cell LymphomaCompletedNCT02013362Phase 1/2
• GAD-M Regimen As First-Line Treatment in Untreated Extranodal NK/T Cell LymphomaStatus unknownNCT01991158Phase 2
• Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell TransplantCompletedNCT01959477Early Phase 1
• High Risk Adult T-cell Leukemia/Lymphoma (ATLL-HR) and Allogeneic TransplantCompletedNCT01941680
• MESA Treatment for NK/T Cell LymphomaStatus unknownNCT01933282Phase 2
• Avastin+ GemAOD As First-Line Treatment in NK/T Cell LymphomaStatus unknownNCT01921790Phase 2
• Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell LymphomaCompletedNCT01902225Phase 1
• A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell LymphomaTerminatedNCT01878708Early Phase 1
• Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic MalignanciesCompletedNCT01871675Phase 1
• Helical Irradiation of Total Skin (HITS) for T Cell LymphomaStatus unknownNCT01854112
• Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell LymphomaCompletedNCT01846390Phase 1
• Therapeutic Efficacy of Topical Sirolimus in Early Stage Cutaneous T-cell Lymphoma (CTCL)WithdrawnNCT01843998Phase 2
• Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)CompletedNCT01839097Phase 1
• CHO(E)P-14 Followed by Alemtuzumab Consolidation in Peripheral T Cell LymphomaCompletedNCT01806337Phase 2
• CD5789 in Early Cutaneous T-Cell Lymphoma (CTCL)CompletedNCT01804335Phase 1
• Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell LymphomaCompletedNCT01796002Phase 3
• A Study of Improving the Efficacy of Treatment in High Risk T Cell Lymphoma PatientsStatus unknownNCT01788137Phase 3
• Phase I/II Clinical Study of Forodesine in Japanese Recurrent/Refractory Peripheral T-cell Lymphoma PatientsCompletedNCT01776411Phase 1/2
• Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin LymphomaWithdrawnNCT01769911Not applicable
• Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic MalignanciesCompletedNCT01767766Phase 1
• MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or LymphomaCompletedNCT01748721Phase 1
• CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell LymphomaStatus unknownNCT01746992Phase 4
• An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study)TerminatedNCT01742793Phase 1
• CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II StudyStatus unknownNCT01719835Phase 2

← Lymphoma, T-Cell, Peripheral overview